Meritage Portfolio Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$1.88M	Sell	37,882 -3,139	-8%	-$153K	0.13%	158
2025 Q3	$1.96M	Sell	41,021 -19,377	-32%	-$780K	0.13%	161
2025 Q2	$1.9M	Buy	60,398 +1,595	+3%	+$51.1K	0.12%	162
2025 Q1	$1.93M	Buy	58,803 +10,622	+22%	+$376K	0.13%	163
2024 Q4	$1.74M	Buy	48,181 +3,886	+9%	+$137K	0.11%	170
2024 Q3	$1.38M	Buy	44,295 +4,328	+11%	+$135K	0.08%	182
2024 Q2	$1.07M	Buy	39,967 +315	+0.8%	+$9.13K	0.07%	197
2024 Q1	$1.35M	Sell	39,652 -3,288	-8%	-$97.9K	0.09%	185
2023 Q4	$1.24M	Buy	42,940 +6,873	+19%	+$182K	0.08%	182
2023 Q3	$994K	Buy	36,067 +19,372	+116%	+$590K	0.07%	196
2023 Q2	$502K	Buy	16,695 +4,020	+32%	+$141K	0.04%	244
2023 Q1	$459K	Buy	12,675 +74	+0.6%	+$2.85K	0.03%	218
2022 Q4	$449K	Buy	12,601 +365	+3%	+$12.7K	0.04%	217
2022 Q3	$414K	Buy	12,236 +524	+4%	+$17.1K	0.03%	224
2022 Q2	$339K	Sell	11,712 -301	-3%	-$8.62K	0.03%	236
2022 Q1	$388K	Buy	12,013 +1,072	+10%	+$32.9K	0.02%	237
2021 Q4	$319K	Buy	10,941 +780	+8%	+$23.7K	0.02%	253
2021 Q3	$271K	Buy	10,161 +630	+7%	+$16.9K	0.02%	254
2021 Q2	$293K	Buy	9,531 +1,512	+19%	+$46.4K	0.02%	254
2021 Q1	$210K	Buy	+8,019	New	+$224K	0.01%	270